CA
VRTX icon

Chatterton & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Chatterton & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Buy
635
+66
+12% +$29.3K 0.19% 74
2026
Q1 		$254K Buy
569
+74
+15% +$34.5K 0.18% 83
2025
Q4 		$224K Buy
+495
New +$213K 0.19% 75

Other funds holding VRTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Chatterton & Associates's VRTX Position: Q2 2026 in Review

Chatterton & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $29.3K and bringing the position to 635 shares worth $315K. The position accounts for 0.19% of the portfolio, ranked #74.

Chatterton & Associates first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 947 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Chatterton & Associates held 635 shares of Vertex Pharmaceuticals worth $315K as of Q2 2026.
  • Chatterton & Associates bought 66 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
  • Vertex Pharmaceuticals made up 0.19% of Chatterton & Associates's portfolio in Q2 2026, its #74 holding.
  • Chatterton & Associates first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 947 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Chatterton & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.